O’Neil Health Care Weekly

XLV rallied for a fourth straight week, gaining 1.9% and now trading just 3% off highs. The sector is set to hit resistance at
$140.82 before all-time highs of $143.42. Should a pullback occur, look for the 21-DMA ($134.94) to act as support. The
relative strength line is nearing highs, warranting an equal to overweight sector positioning.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 regained its 200-DMA (4,046) this week and is now
consolidating gains above all key moving averages. Support below this level is the rising 21-DMA (3,960) with the next
level of resistance at the September high of 4,119. The Nasdaq is still finding resistance at its 100-DMA (11,503) with the
next level above that at the rolling 200-DMA (12,026). The distribution day count stands at five and three, respectively, with
two days expiring on the S&P 500 and one on the Nasdaq next week.

O’Neil Health Care Weekly

XLV gained 88bps last week but is still facing resistance at the August high of $134.47. The next level above that is
~$137.50. Support remains the flattened 200-DMA ($130.16). Though the relative strength line rallied from oversold levels,
it remains well off highs, warranting an equal to slightly overweight sector positioning. Overall, despite the two-week lag,
this ETF still looks intact on an absolute basis as its one of few trading above all key moving averages.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 rallied from 100-DMA (3,918) support this week to close just below logical near-term resistance at its rolling 200-DMA (4,057). Resistance above this level is the September high of 4,119. The Nasdaq, which is trading ~30% off highs, held 50-DMA (10,907) support despite still trading below near-term resistance at it 100-DMA (11,510). Resistance above this level is the falling 200-DMA (12,094). The distribution day count stands at six and two, respectively, with two days expiring on the S&P 500 and one on the Nasdaq next week.

O’Neil Health Care Weekly

XLV gained 88bps last week but is still facing resistance at the August high of $134.47. The next level above that is
~$137.50. Support remains the flattened 200-DMA ($130.16). Though the relative strength line rallied from oversold levels,
it remains well off highs, warranting an equal to slightly overweight sector positioning. Overall, despite the two-week lag,
this ETF still looks intact on an absolute basis as its one of few trading above all key moving averages.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq pulled back this week, consolidating
very sharp one-week gains above near-term support at the 100-DMA (3,910) and 50-DMA (10,956), respectively. The S&P
500 still faces resistance at the rolling 200-DMA (4,067) followed by the September high of 4,119. The Nasdaq touched
100-DMA (11,511) resistance Tuesday before pulling back to support over the last three sessions. The distribution day
count stands at six and two, respectively

Market View

The U.S. market is in a Confirmed Uptrend. The S&P 500 and Nasdaq gapped up 6% and 8% respectively this week and regained key levels of resistance. The S&P 500 is trading above its 100-DMA (3,904) for the first time since early September and quickly approaching the next level of resistance at its 200-DMA (4,081). The Nasdaq broke through its 50-DMA (11,014) and October highs (11,210) but will face resistance at its 100-DMA (11,518). The distribution day count stands at five and two respectively.